GlassScriptPhysician profile
Kamesh Gupta
NPI 1497232920
$2,744.13
in general payments reported to CMS, 2019-2025
21 companies · $1,898 in 2025
The $1,898 reported for 2025 was more than what 78% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $109 · 2024: $737 · 2025: $1,898.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,939 · Travel and Lodging: $529 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,939.14 |
| Travel and Lodging | $528.56 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $905.36 | 2025 | Spyglass, General - Biliary Devices, Apollo Esg Nxt System |
| Abbvie INC. | $554.71 | 2024-2025 | |
| Qol Medical, LLC | $181.93 | 2024-2025 | Sucraid, Sucraid |
| Janssen Biotech, INC. | $158.67 | 2024-2025 | Stelara, Simponi, Simponi Aria |
| Gilead Sciences, INC. | $124.91 | 2024 | Epclusa |
| Madrigal Pharmaceuticals | $92.04 | 2025 | Rezdiffra |
| Regeneron Healthcare Solutions, INC. | $77.76 | 2024-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $75.02 | 2025 | Eohilia, Entyvio |
| Genzyme Corporation | $69.38 | 2024-2025 | |
| Celltrion USA INC. | $54.48 | 2025 | Vegzelma |
| Merck Sharp & Dohme LLC | $45.79 | 2024-2025 | Bridion |
| Phathom Pharmaceuticals, INC. | $38.85 | 2024-2025 | Voquezna |
| Pfizer INC. | $26.29 | 2025 | |
| Ferring Pharmaceuticals INC. | $23.15 | 2025 | Rebyota |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.60 | 2025 | Xifaxan |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Corporation of The Americas | $21.24 | 2024 | Visiglide |
| Daiichi Sankyo INC. | $19.10 | 2024 | Injectafer |
| Sandoz INC. | $18.46 | 2025 | Pyzchiva |
| Braintree Laboratories, INC. | $14.75 | 2024 | Sutab, Suflave |
| Amgen INC. | $14.63 | 2025 | Uplizna |
| Ironwood Pharmaceuticals, INC | $14.57 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kamesh Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.